Pacira Pharma (PCRX) Misses Q3 EPS by 6c

Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.72, $0.06 worse than the analyst estimate of $0.78. Revenue for the quarter came in at $163.93 million versus the consensus estimate of $173.42 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• Qualcomm expects $40bn in non-handset revenue by fiscal 2029
• Currenc Group suspends Indonesian WalletKu unit operations